Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of tezacaftor + ivacaftor in children with cystic fibrosis and F508del-CFTR mutation
2016-004479-35Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of tezacaftor and ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Absolute change in lung clearance index 2.5 from baseline through Week 8. Started Feb 2018; status: completed.
02
Drugs
tezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2016-004479-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004479-35.